{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-039269","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.077080+00:00","generated_at":"2026-05-30T21:34:39.416007+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncocyte raises $10.2M in private placement, adds two major transplant centers as customers","bullets":["Private placement of 3.46M shares at $2.948/share raises ~$10.2M gross; includes participation from strategic partner Bio-Rad.","Proceeds for working capital and general corporate purposes; closing expected October 4, 2024.","Two leading transplant university hospitals in U.S. and Germany adopt GraftAssure research assay for graft damage monitoring.","Submitted Q-Sub to FDA for IVD version of dd-cfDNA test; FDA meeting scheduled for early December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-039269","json":"https://secwatch.observer/filing/0001493152-24-039269.json","markdown":"https://secwatch.observer/filing/0001493152-24-039269.md","text":"https://secwatch.observer/filing/0001493152-24-039269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224039269/0001493152-24-039269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224039269/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:34:39.416007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}